HIV-1, HIV Infections
Conditions
Keywords
HIV preventive vaccine
Brief summary
Objectives: Safety and immunogenicity of MVA.HIVA vaccine in 20-week-old healthy Gambian infants born to HIV-1/2-uninfected mothers. Gross impact of MVA.HIVA on the immunogenicity of EPI vaccines (DTwPHib, HepB, PCV-7 and OPV) when administered at 20 weeks (4 weeks after the last EPI vaccines), who have had BCG vaccine within the first 4 weeks of life.
Interventions
BIOLOGICALMVA.HIVA
1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
Sponsors
European and Developing Countries Clinical Trials Partnership (EDCTP)
Medical Research Council
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
No minimum to 3 Days
Healthy volunteers
Yes
Inclusion criteria
* Healthy infants, 19 weeks of age, with weight for age z-scores within 2 standard deviations of normal. * Have received all standard EPI immunizations according to national immunization programme. * Written informed consent by parent. * Mother HIV-1/2-uninfected.
Exclusion criteria
* Acute disease at the time of vaccination (acute disease is defined as the presence of a moderate or severe illness with or without fever). All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory tract infection with or without low-grade febrile illness, i.e. axillary temperature of \<37.5 °C ). * Axillary temperature of ≥ 37.5 °C at the time of vaccination. * Any clinically significant abnormal finding on screening from biochemistry or haematology at 19 weeks. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products. * Presence of any underlying disease that compromises the diagnosis and evaluation of response to the vaccine. * Invasive bacterial infections (pneumonia, meningitis). * Any other on-going chronic illness requiring hospital specialist supervision. * Administration of immunoglobulins and/or any blood products within one month preceding the planned administration of the vaccine candidate. * Any history of anaphylaxis in reaction to vaccination. * Research physician's assessment of lack of willingness by parents to participate and comply with all requirements of the protocol, or identification of any factor felt to significantly increase the infant's risk of suffering an adverse outcome. * Likelihood of travel away from the study area. * Untreated malaria infection. * Any other clinical evidence of infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For safety and reactogenicity: Actively and passively collected data on adverse events | Up to 16 weeks after vaccination |
Secondary
| Measure | Time frame |
|---|---|
| For immunogenicity: Frequency of IFN-γ producing cells determined in ex-vivo (effector) and 10-day cultured (memory) ELISPOT assays after overnight stimulation with pools of HIVA-derived peptides | Up to 16 weeks after vaccination |
| For immunity to EPI vaccines: Antibody levels to specific vaccines. | 1 week before and 1 week after vaccination |
Countries
The Gambia
Outcome results
None listed